FUTURE OF HEALTHCARE
Omnicell | February 15, 2022
Omnicell, Inc., a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that UMC Health System (“UMC”) in Lubbock, Texas, has selected Omnicell’s comprehensive portfolio of Advanced Services solutions to support key pharmacy initiatives, including acute care, outpatient, retail, and 340B program strategies.
UMC has signed a 10-year sole source agreement for Omnicell’s cloud-based portfolio of solutions, including central pharmacy automation and point of care dispensing systems. The partnership is also expected to support UMC’s goals of expanding community pharmacy services through opportunities with Omnicell’s 340B services and EnlivenHealth’s patient engagement solutions, helping UMC to drive operational efficiency across its continuum of care. More importantly, these solutions will empower pharmacy staff and clinicians to focus on higher value tasks that support patient safety.
As a public hospital with a 40-year tenure supporting the Lubbock community, UMC has experienced an increase in demand for its services. According to U.S. Census data, Texas has one of the highest uninsured population rates – at 18.4 percent in 2019, nearly double the national average. Programs like the federal 340B Drug Pricing Program and technology-enabled patient engagement solutions are intended to help improve health outcomes for these underserved communities.
“At UMC, our top priority is patient safety and ensuring healthy outcomes for our community. Partnering with Omnicell, we are building an advanced pharmacy technology strategy that aligns with our vision to streamline and advance the pharmacy and nursing practice across our system. Most importantly, we are laying a technology foundation that will enable the best patient care.”
John Lowe, vice president of Support Services at UMC Health System
UMC has embraced the industry-defined vision of the Autonomous Pharmacy, a roadmap designed to develop a zero-error, fully automated medication management infrastructure. Through automation, intelligence, and expert services, the Autonomous Pharmacy is expected to drive performance and outcomes, and empower clinicians to shift their focus from manual administrative functions to patient support needs.
“As medication management becomes more complex, we believe health systems need end-to-end, cloud-based solutions that will allow them to work smarter, while supporting safe, efficient pharmacy care,” said Scott Seidelmann, executive vice president and chief commercial officer at Omnicell. “We’re confident that Omnicell’s partnership with UMC will provide comprehensive solutions that bridge acute and ambulatory care to help enhance performance and that are designed to deliver the highest levels of patient safety across the health system.”
UMC Health System is a national award-winning health system comprised of over 4,600 team members and more than 30 care locations. We are proud to partner with Texas Tech University Health Sciences Center to provide the best care to West Texas and Eastern New Mexico. Whether you are managing a chronic condition, dealing with an unexpected illness, or simply working to stay healthy, we are passionate about getting you well and helping you stay that way. At UMC, Our Passion is You.
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.
FUTURE OF HEALTHCARE
Spinafx medical inc | June 13, 2022
Minimally invasive image-guided therapy company, SpinaFX Medical Inc. announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting inBoston, MA,June 11-16, at booth 414. Dr. Alexis Kelekis, medical advisor to SpinaFX, will present the results of a research study on which he was the lead author, recently published inThe Spine Journal, on the effectiveness of intradiscal oxygen-ozone treatment compared to microdiscectomy for contained lumbar disc herniation with radiculopathy. This study has been recognized by SIR as one of the 2022Abstracts of the Year.
"We are excited to meet with some of the world's leading interventional radiologists to discuss innovations in minimally invasive, image-guided care and share our recent progress and momentum at SpinaFX. We look forward to Dr. Kelekis' presentation and celebrate the study's findings, which have the potential to benefit both patients and providers by addressing a significant gap in the continuum of care for the millions suffering from back pain."
Jeff Cambra, SpinaFX CEO
"I am thrilled that Dr. Kelekis will share the findings of our skilled research team at SIR's Annual Scientific Meeting," said Dr.Kieran Murphy, SpinaFX Chief Medical Officer and co-author of the recognized study. "The technology used in this randomized control trial holds great promise for patients struggling with contained herniated lumbar disc pain and it is an honor to have this research recognized by such a prestigious and well-respected organization."
Dr. Alexis Kelekis willpresentthe results of his study onWednesday, June 15, at10:40 a.m.during Closing Plenary.
As an exhibitor during the meeting onJune 11-16, SpinaFX will offer attendees the opportunity to discuss the study results and their implications with Drs. Kelekis and Murphy, learn more about SpinaFX and its goal to help develop minimally invasive, image-guided treatment options, and provide input on developing technology with the potential to redefine the treatment of contained herniated discs. Visit SIR'swebsiteto learn more about the Annual Scientific Meeting.
Headquartered inOntario, Canada, SpinaFX is a treatment solution and technology company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to contained herniated discs.
Lark Health | March 17, 2022
Lark Health today announced the development of a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease and coronary artery disease in collaboration with Roche Diagnostics. The program, named Lark Heart Health, is an AI-driven virtual care solution that provides personalized health coaching anytime, anywhere. The new Heart Health program is planned to launch later this year.
Cardiovascular disease is the leading cause of death globally, and nearly half of all adults in the U.S. have some form of CVD. It's also one of the most expensive chronic conditions, with heart disease and stroke costing the U.S. healthcare system roughly $214 billion annually. Yet, provider shortages and siloed care teams leave patients with limited care options, gaps in care, and insufficient education and empowerment to self-manage their heart health. Additionally, high treatment costs and resource constraints often limit care to those with the highest acuity conditions.
Built using a Cognitive Behavioral Therapy framework and designed in accordance with guidelines from the American Heart Association (AHA), Lark Heart Health will provide a cost-effective, scalable solution for continuous, person-centric remote heart health coaching intended to help users improve their healthy lifestyle behaviors, reduce stress levels, and ultimately decrease risk factors for heart disease. Through an evidence-based educational curriculum and real-time personalized coaching, Lark will provide users with the tools they need to make meaningful lifestyle changes that can help them better prevent and manage ASCVD and CAD.
Earlier this year, Lark announced it had joined the AHA's Network at American Heart Association Center of Health Technology & Innovation, which is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
"Lark Heart Health will help those at high risk prevent and actively manage cardiovascular disease through personalized digital coaching. By leveraging our AI technology, we can deliver meaningful and engaging care at an unprecedented scale, and this collaboration with Roche Diagnostics will support the expansion of our proven tech platform into one of the costliest chronic disease markets."
Julia Hu, co-founder and CEO of Lark
About Lark Health
Lark is a healthcare technology company aimed at delivering infinitely scalable, virtual chronic and preventative healthcare through conversational AI. To date, Lark has provided nearly 2 million people with unlimited, 24/7 personalized care delivered through an easy-to-use, text message-like interface that integrates remote patient monitoring tools and is built on a cognitive behavioral therapy framework. Lark's platform seamlessly integrates with health plans' and employers' existing healthcare infrastructure to help them scale their chronic disease prevention and management programs, boost engagement, and improve health outcomes. Lark currently works with many of the largest health plans and across four programs: Prevention, Diabetes Prevention, Diabetes Care, and Hypertension Care. Lark's Diabetes Prevention Program, which is the fastest growing and lowest cost DPP, has received the highest level of clinical recognition—Full Recognition—from the Centers for Disease Control and Prevention. The company has received numerous accolades, including having been named as one of CB Insights Digital Health 150 (2019), a finalist for the UCSF Digital Health Awards one of Fast Company's Most Innovative Companies and one of Fierce Healthcare's Fierce 15.
Exela Technologies | January 12, 2022
Exela Technologies, Inc. (“Exela”)today announced that it continues to expand its relationship with a leading health insurance organization that spans almost two decades. This customer continues to accelerate deployment of Exela’s PCH Global platform to speed up their digital transformation and improve both the member and provider experience. The latest expansion is valued at $6.2 million of additional contract value revenue.
Exela continues to invest in expanding PCH Global’s capabilities to provide a cloud hosted solution with one of the best edit resolutions for healthcare claims. This extension of deployment marks another milestone in the value proposition of the PCH Global platform to digitally connect members, providers and insurance companies to enable clean claims, payment transparency and digital appeals. PCH Global’s cloud network also offers increased scalability, the highest uptime and best business continuity protections. PCH Global has robust data analytics which are continually improving as Exela processes more and more data. Additionally, PCH Global’s improved data analytics can be accessed via a self-service model.
“We are proud of our long standing partnership and privileged to be part of customer’s digital transformation journey. Adoption of our PCH Global platform continues to address healthcare industry’s goal to deliver most efficient, cost effective and best healthcare to the members.”
Suresh Yannamani, President of Exela
About Exela Technologies
Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of experience operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune® 100. Utilizing foundational technologies spanning information management, workflow automation, and integrated communications, Exela’s software and services include multi-industry, departmental solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and the public sector. Through cloud-enabled platforms, built on a configurable stack of automation modules, and over 17,500 employees operating in 23 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner.